Skip to main content
. 2023 Feb 28;146(7):2717–2722. doi: 10.1093/brain/awad063

Figure 1.

Figure 1

The P2P platform trial. The P2P platform trial plans to recruit people at risk of developing PD on the basis of known genetic risks and/or prodromal symptoms such as REM sleep behaviour disorder to identify treatments which prevent or delay the conversion to motor PD. The EJS ACT-PD platform plans to recruit people with established motor PD to identify treatments that will prevent or delay subsequent progression of motor and non-motor symptoms.